Ciprofibrate is a PPARα agonist that exhibits anti-hyperlipidemic activity. Clinically, ciprofibrate decreases levels of triglycerides and total cholesterol and increases levels of HDL. In hepatoma cells, ciprofibrate increases NF-κB DNA binding activity. Additionally, ciprofibrate induces depolarization of the mitochondrial membrane potential, which may be involved in its mechanism of enhancing peroxisome proliferation.
| Cas No. | 52214-84-3 |
|---|---|
| Purity | ≥98% |
| Formula | C13H14Cl2O3 |
| Formula Wt. | 289.16 |
| IUPAC Name | 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid |
| Melting Point | 114-120°C |
| Solubility | Practically insoluble in water, freely soluble in anhydrous ethanol, soluble in toluene |
| Appearance | White or Light Yellow Crystal Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C3260 Info Sheet PDF |
|---|
Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, et al. Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study). Cardiovasc Diabetol. 2004 Jul 23;3:8. PMID: 15272932.
Li Y, Glauert HP, Spear BT. Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E. Biochem Pharmacol. 2000 Feb 15;59(4):427-34. PMID: 10644051.
Zhou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999 Mar;48(1):82-9. PMID: 10330687.
